The Prognostic Value of the Platelet-to-lymphocyte Ratio in Multiple Myeloma Patients Treated with a Bortezomib-based Regimen

Overview

Journal Sci Rep

Date 2025 Jan 13

PMID 39805912

Authors

Quane Zhang

Yifan Wang

Wenting Shi

Yue Chen

Zhengmei He

Liang Yu

Chunling Wang

Affiliations

Soon will be listed here.

Abstract

Multiple myeloma (MM) is the second most common hematological malignancy. Previous studies have validated the prognostic significance of the platelet-to-lymphocyte ratio (PLR) in patients with certain solid tumors. However, the relationship between the PLR and prognosis in myeloma patients has not been clearly demonstrated. In our study, we included 122 newly diagnosed MM patients who were treated with bortezomib-based chemotherapy. These patients were divided into low-PLR and high-PLR groups based on their initial PLR values. We compared the clinical characteristics between the two groups and utilized restricted cubic splines (RCSs) in the regression model to estimate the nonlinear relationship between the initial PLR and overall survival (OS) in MM patients. The results showed that patients in the low-PLR group had significantly worse OS (P = 0.00031) and progression-free survival (PFS) (P < 0.0001) compared to those in the high-PLR group. Furthermore, within the higher-risk MM group, a low PLR was also associated with worse OS (P = 0.0037) and PFS (P = 0.0048). Therefore, a low PLR was identified as an independent predictor of poor OS in MM patients. The RCS curves further confirmed a significant nonlinear relationship between the PLR and OS in patients with MM. The PLR may serve as a significant independent prognostic indicator for MM patients undergoing bortezomib-based chemotherapy, and there exists a crucial nonlinear relationship between the PLR and OS in these patients.

References

More S, Corvatta L, Manieri V, Saraceni F, Scortechini I, Mancini G . Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?. Cells. 2022; 11(4). PMC: 8870632. DOI: 10.3390/cells11040606. View

Soekojo C, Chng W . The evolution of immune dysfunction in multiple myeloma. Eur J Haematol. 2022; 109(5):415-424. DOI: 10.1111/ejh.13839. View

Cho M, Bottsford-Miller J, Vasquez H, Stone R, Zand B, Kroll M . Platelets increase the proliferation of ovarian cancer cells. Blood. 2012; 120(24):4869-72. PMC: 3520623. DOI: 10.1182/blood-2012-06-438598. View

Mendez-Ferrer S, Bonnet D, Steensma D, Hasserjian R, Ghobrial I, Gribben J . Bone marrow niches in haematological malignancies. Nat Rev Cancer. 2020; 20(5):285-298. PMC: 9912977. DOI: 10.1038/s41568-020-0245-2. View

Mantovani A, Garlanda C . Inflammation and multiple myeloma: the Toll connection. Leukemia. 2006; 20(6):937-8. DOI: 10.1038/sj.leu.2404229. View

Liu J, Zhang B, Zhang G, Shang D . Reprogramming of regulatory T cells in inflammatory tumor microenvironment: can it become immunotherapy turning point?. Front Immunol. 2024; 15:1345838. PMC: 10915070. DOI: 10.3389/fimmu.2024.1345838. View

van de Donk N, Pawlyn C, Yong K . Multiple myeloma. Lancet. 2021; 397(10272):410-427. DOI: 10.1016/S0140-6736(21)00135-5. View

Yang S, Shen W, Hu J, Cai S, Zhang C, Jin S . Molecular mechanisms and cellular functions of liquid-liquid phase separation during antiviral immune responses. Front Immunol. 2023; 14:1162211. PMC: 10210139. DOI: 10.3389/fimmu.2023.1162211. View

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst H, Goldschmidt H, Rosinol L . Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015; 33(26):2863-9. PMC: 4846284. DOI: 10.1200/JCO.2015.61.2267. View

10.

Chae Y, Oh M, Giles F . Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. Oncologist. 2017; 23(4):410-421. PMC: 5896702. DOI: 10.1634/theoncologist.2017-0354. View

11.

Ho-Tin-Noe B, Boulaftali Y, Camerer E . Platelets and vascular integrity: how platelets prevent bleeding in inflammation. Blood. 2017; 131(3):277-288. DOI: 10.1182/blood-2017-06-742676. View

12.

Fritz E, Ludwig H, Scheithauer W, Sinzinger H . Shortened platelet half-life in multiple myeloma. Blood. 1986; 68(2):514-20. View

13.

Shi L, Qin X, Wang H, Xia Y, Li Y, Chen X . Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma. Oncotarget. 2016; 8(12):18792-18801. PMC: 5386647. DOI: 10.18632/oncotarget.13320. View

14.

Guan Y, Xiong H, Feng Y, Liao G, Tong T, Pang J . Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis. Prostate Cancer Prostatic Dis. 2020; 23(2):220-231. DOI: 10.1038/s41391-020-0209-3. View

15.

Podar K, Chauhan D, Anderson K . Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 2008; 23(1):10-24. PMC: 3418600. DOI: 10.1038/leu.2008.259. View

16.

Lust J, Lacy M, Zeldenrust S, Witzig T, Moon-Tasson L, Dinarello C . Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma. Am J Hematol. 2016; 91(6):571-4. DOI: 10.1002/ajh.24352. View

17.

Wongrakpanich S, George G, Chaiwatcharayut W, Biso S, Candelario N, Mittal V . The Prognostic Significance of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Patients With Multiple Myeloma. J Clin Lab Anal. 2016; 30(6):1208-1213. PMC: 6807214. DOI: 10.1002/jcla.22004. View

18.

Zhang X, Duan J, Wen Z, Xiong H, Chen X, Liu Y . Are the Derived Indexes of Peripheral Whole Blood Cell Counts (NLR, PLR, LMR/MLR) Clinically Significant Prognostic Biomarkers in Multiple Myeloma? A Systematic Review And Meta-Analysis. Front Oncol. 2021; 11:766672. PMC: 8650157. DOI: 10.3389/fonc.2021.766672. View

19.

Saeed L, Patnaik M, Begna K, Al-Kali A, Litzow M, Hanson C . Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients. Blood Cancer J. 2017; 7(3):e550. PMC: 5380913. DOI: 10.1038/bcj.2017.30. View

20.

Scherlinger M, Richez C, Tsokos G, Boilard E, Blanco P . The role of platelets in immune-mediated inflammatory diseases. Nat Rev Immunol. 2023; 23(8):495-510. PMC: 9882748. DOI: 10.1038/s41577-023-00834-4. View